Information  X 
Enter a valid email address

Protherics PLC (PTI)

  Print      Mail a friend       Annual reports

Tuesday 28 October, 2008

Protherics PLC

Director/PDMR Shareholding

RNS Number : 8912G
Protherics PLC
28 October 2008
 



Protherics PLC


Notification of Directors' Interests



London, UK; Brentwood, TN, US: 28 October 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, in accordance with the FSA Disclosure and Transparency Rules, announces that, on 23 October 2008, pursuant to the conversion of all outstanding six per cent. unsecured convertible loan notes 2010 of Protherics, the following ordinary shares (the "Shares") were allotted to Directors of Protherics PLC:


Director

Nominal Value of Loan Notes converted

Shares allotted share capital

% issued

Andrew Heath

£24,242

96,968

0.028%

Stuart Wallis

£60,606

242,424

0.069%


In accordance with the Loan Note Instrument, the Shares were allotted at a price of 25 pence per share.


Following the above allotment of Shares, their interests in the ordinary share capital of the Company are as follows:



No. Shares

% issued share capital

Andrew Heath

516,778

0.148%

Stuart Wallis

809,113

0.231%


| Ends |


For further information please contact:


Protherics 


Nick Staples, Director of Corporate Affairs

+44 (0) 7919 480510  

Julie Vickers, Company Secretary 

+44 (0)1928 518010



Financial Dynamics - press enquiries


London: Ben Atwell, Lara Mott

+44 (0) 20 7831 3113 

New York: John Capodanno

+1 212 850 5600


Or visit  www.protherics.com


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSMPBPTMMTTBJP